Acuitas Therapeutics
Vancouver, BC
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (11)
○ EMA GMP
○ MHRA GMP
Quick Facts: Acuitas Therapeutics
- Signal Score
- 56.5/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Vancouver, BC
- Modalities
- mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed — 6 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Acuitas Therapeutics
Reagent/raw material supplier.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 6 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Vancouver, BC
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals11 articles (not scored)
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 11 articles
Company announcements, not verified evidence. They do not change any score.
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Nigeria
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com Investing.com Nigeria
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com South Africa
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com Investing.com South Africa
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy - TipRanks
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy TipRanks
Genflow partners with Acuitas for gene therapy delivery tech - Investing.com
Genflow partners with Acuitas for gene therapy delivery tech Investing.com
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Australia
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com Investing.com Australia
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com UK
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com Investing.com UK
Circio and Acuitas partner on circular RNA CAR T therapy - Drug Target Review
Circio and Acuitas partner on circular RNA CAR T therapy Drug Target Review
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - TradingView — Track All Markets
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics TradingView
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology - marketscreener.com
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology marketscreener.com
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - Finansavisen
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics Finansavisen
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement - marketscreener.com
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement marketscreener.com
Frequently Asked Questions About Acuitas Therapeutics
What is Acuitas Therapeutics's CDMO Signal Score?
Acuitas Therapeutics has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating Acuitas Therapeutics for a manufacturing program?
Use the free AI matchmaker to compare Acuitas Therapeutics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Evonik Health Care
Birmingham, AL · Vancouver, BC
Signal Score: 81.5
mRNA, Biologics
Precision NanoSystems (Cytiva)
Vancouver, BC, Canada
Signal Score: 60.5
mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Compare Acuitas Therapeutics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.